查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1631177

Gabapentin市场规模、份额、趋势分析报告：按剂型、类型、应用、分销管道、地区、细分预测，2025-2030 年

Gabapentin Market Size, Share & Trends Analysis Report By Dosage Form (Tablet, Capsule, Oral Solution), By Type (Generic, Branded), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

Gabapentin市场成长与趋势

根据Grand View Research, Inc.的最新报告，全球Gabapentin市场规模预计到2030年将达到30.7亿美元，2025年至2030年期间的复合年增长率为5.2%。

这种增长是由于Gabapentin在治疗神经病变疼痛方面的使用量不断增加，以及癫痫等相关疾病的全球发病率不断上升所致。另一个主要的成长要素是老年人口的增加，他们更容易患癫痫和神经性疼痛等疾病。

学名药需求的不断增长为大型学名药製造商创造了机会，但由于对学名药的偏好较高，中低收入国家的机会更为有利可图。此外，北美和欧洲等已开发地区正在进行政策变化，透过推广使用Gabapentin等学名药来减轻其医疗系统的负担。

Gabapentin主要有三种剂型：锭剂、胶囊和口服液。由于领先品牌产品的存在和易于获得，胶囊在 2022 年占据了最大的市场占有率。Gabapentin被发现有成瘾和过量摄取的风险，导致一些国家对其使用进行严格审查和限制。这些发现可能会影响Gabapentin的长期成长，促使药厂专注于开发更安全、更有效的止痛药。

由于北美发达的医疗保健体系鼓励采用Gabapentin等药物，预计北美将在预测期内占据市场主导地位。然而，由于主要学名药参与企业的出现，以及人们对采用药物治疗方法而非亚洲国家主要使用的传统治疗方法的认识不断提高，亚太地区等其他地区正在以更快的速度增长。

Gabapentin产业的主要竞争对手包括 Sun Pharmaceutical Industries Ltd.、Ascend Laboratories, LLC、Apotex Inc.、Teva Pharmaceutical Industries Ltd.、Arbor Pharmaceuticals, Inc. 和 Pfizer Inc.随着品牌产品的衰落，竞争正在转向非专利产品。这导致市场对参与企业和新产品的饱和状态，从而导致竞争对手之间的敌意加剧。

Gabapentin市场报告重点

  • 胶囊将占据市场主导地位，到 2024 年将占 56.1% 的份额。这是因为它易于管理，使其成为包括儿童和老人在内的患者的理想选择。
  • 仿製学名药Gabapentin占据市场主导地位，2024 年的销售份额为 90.1%。学名药提供了比品牌药更具成本效益的替代品，扩大了更广泛患者获得药物的管道。
  • 癫痫应用在 2024 年占据了 49.9% 的最大市场占有率，因为它被证明是一种抗惊厥药物，对于癫痫患者的癫痫发作管理至关重要。
  • 医院药局占据市场主导地位，到 2024 年将占 47.6% 的份额。这是因为它是治疗癫痫和神经病变疼痛等慢性疾病的重要医疗中心。
  • 北美Gabapentin市场占据全球市场主导地位，2024 年的销售份额为 33.7%。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章Gabapentin市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析 – 波特五力分析
    • PESTLE分析

第四章Gabapentin市场：剂型业务分析

  • 2024 年及 2030 年剂型市场占有率
  • 剂型细分细分仪表板
  • 2018-2030 年剂型市场规模、预测及趋势分析
  • 锭剂
  • 胶囊
  • 口服液

第 5 章Gabapentin市场：类型业务分析

  • 2024 年及 2030 年类型市场占有率
  • 类型细分仪表板
  • 2018 年至 2030 年按类型分類的市场规模、预测与趋势分析
  • 非专利的
  • 品牌

第六章Gabapentin市场：应用业务分析

  • 2024 年和 2030 年应用市场占有率
  • 应用程式细分仪表板
  • 2018 年至 2030 年按应用分類的市场规模、预测与趋势分析
  • 癫痫
  • 神经病变疼痛
  • 不宁腿
  • 其他的

第七章Gabapentin市场：分销通路业务分析

  • 分销通路市场占有率，2024 年和 2030 年
  • 分销通路细分仪表板
  • 2018 年至 2030 年按分销管道分類的市场规模、预测和趋势分析
  • 医院药房
  • 零售药局
  • 网路药局

第 8 章Gabapentin市场：区域、估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 市场规模、预测趋势分析，2018-2030
  • 北美洲
    • 按国家/地区，2018 年至 2030 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区，2018 年至 2030 年
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 按国家/地区，2018 年至 2030 年
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 按国家/地区，2018 年至 2030 年
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 按国家/地区，2018 年至 2030 年
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争格局

  • 参与者概述
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Zydus Pharmaceuticals, Inc.
    • GLENMARK PHARMACEUTICALS LTD.
    • Sun Pharmaceutical Industries Ltd.
    • Ascend Laboratories LLC
    • Apotex Inc.
    • Teva Pharmaceutical Industries Ltd
    • Aurobindo Pharma
    • Amneal Pharmaceuticals LLC.
    • Cipla
    • BP Pharma
    • Assertio Holdings, Inc.
    • Arbor Pharmaceuticals, LLC（Azurity Pharmaceuticals, Inc.）
    • Pfizer Inc.
Product Code: GVR-4-68040-043-6

Gabapentin Market Growth & Trends:

The global gabapentin market size is expected to reach USD 3.07 billion by 2030, expanding at a CAGR of 5.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth can be attributed to the rising usage of gabapentin for neuropathic pain and the increasing incidence of associated diseases such as epilepsy globally. The other key growth driver is the rising geriatric population which is more to epilepsy and conditions such as neuropathic pain.

The growing demand for generics in the market is creating an opportunity for major generic players, however, the opportunity is more lucrative in the lower and middle-income nations due to the high preference for these drugs. Moreover, developed regions such as North America and Europe are further making policy changes to reduce the burden on the healthcare system by promoting the use of generics such as gabapentin.

Gabapentin is majorly available in three dosage forms, namely, tablet, capsule, and oral solution. The capsules segment held the largest market share in 2022, owing to the presence of major branded products and the ease of availability. Due to the discovery that gabapentin carries a risk of addiction and overdose, some nations have scrutinized its usage and placed limitations on it. Long-term growth for gabapentin may be impacted by such discoveries, which may push drugmakers to concentrate on creating safer and more potent painkillers.

North America is expected to dominate the market over the forecast period, due to a developed healthcare system that facilitates the adoption of drugs such as gabapentin. However, other regions such as Asia Pacific are growing at a faster rate attributable to the presence of key generic players and the rising awareness about the adoption of pharmaceutical treatments for diseases over traditional therapies, majorly used in Asian countries.

Some of the key competitors in the gabapentin industry include Sun Pharmaceutical Industries Ltd.; Ascend Laboratories, LLC; Apotex Inc.; Teva Pharmaceutical Industries Ltd.; Arbor Pharmaceuticals, Inc.; and Pfizer Inc. The downfall of branded products is leading to the shift of competition toward generic products. This is increasing the competitive rivalry due to increased marketplace saturation of players and products.

Gabapentin Market Report Highlights:

  • Capsules dominated the market and accounted for a share of 56.1% in 2024. This is attributed to their ease of administration, which makes them ideal for patients, including children and the elderly.
  • Generic gabapentin led the market with a revenue share of 90.1% in 2024. Generics provide a cost-effective alternative to branded medications, expanding accessibility for a wider patient demographic.
  • Applications in epilepsy held the largest market share of 49.9% in 2024, owing to its proven efficacy as an anticonvulsant essential for seizure management in individuals with epilepsy.
  • Hospital pharmacies dominated the market and accounted for a share of 47.6% in 2024, serving as key healthcare facilities for treating chronic conditions such as epilepsy and neuropathic pain.
  • North America gabapentin market dominated the global market with a revenue share of 33.7% in 2024.

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Dosage Form
    • 1.2.2. Type
    • 1.2.3. Application
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Gabapentin Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Gabapentin Market: Dosage Form Business Analysis

  • 4.1. Dosage Form Market Share, 2024 & 2030
  • 4.2. Dosage Form Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
  • 4.4. Tablet
    • 4.4.1. Tablet Market, 2018 - 2030 (USD Million)
  • 4.5. Capsule
    • 4.5.1. Capsule Market, 2018 - 2030 (USD Million)
  • 4.6. Oral Solution
    • 4.6.1. Oral Solution Market, 2018 - 2030 (USD Million)

Chapter 5. Gabapentin Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Generic
    • 5.4.1. Generic Market, 2018 - 2030 (USD Million)
  • 5.5. Branded
    • 5.5.1. Branded Market, 2018 - 2030 (USD Million)

Chapter 6. Gabapentin Market: Application Business Analysis

  • 6.1. Application Market Share, 2024 & 2030
  • 6.2. Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Epilepsy
    • 6.4.1. Epilepsy Market, 2018 - 2030 (USD Million)
  • 6.5. Neuropathic Pain
    • 6.5.1. Neuropathic Pain Market, 2018 - 2030 (USD Million)
  • 6.6. Restless Legs Syndrome
    • 6.6.1. Restless Legs Syndrome Market, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Gabapentin Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Gabapentin Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Gabapentin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Gabapentin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Gabapentin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Gabapentin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Gabapentin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Zydus Pharmaceuticals, Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. GLENMARK PHARMACEUTICALS LTD.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Sun Pharmaceutical Industries Ltd.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Ascend Laboratories LLC
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Apotex Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Teva Pharmaceutical Industries Ltd
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Aurobindo Pharma
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Amneal Pharmaceuticals LLC.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Cipla
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. B.P. Pharma
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. Assertio Holdings, Inc.
      • 9.5.11.1. Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives
    • 9.5.12. Arbor Pharmaceuticals, LLC (Azurity Pharmaceuticals, Inc.)
      • 9.5.12.1. Overview
      • 9.5.12.2. Financial Performance
      • 9.5.12.3. Product Benchmarking
      • 9.5.12.4. Strategic Initiatives
    • 9.5.13. Pfizer Inc.
      • 9.5.13.1. Overview
      • 9.5.13.2. Financial Performance
      • 9.5.13.3. Product Benchmarking
      • 9.5.13.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global gabapentin market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 5. Global gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 6. Global gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 7. Global gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8. North America gabapentin market, by country, 2018 - 2030 (USD Million)
  • Table 9. North America gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 10. North America gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 11. North America gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 12. North America gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13. U.S. gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 14. U.S. gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 15. U.S. gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 16. U.S. Gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Canada gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 18. Canada gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 19. Canada gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 20. Canada gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21. Mexico gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 22. Mexico gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 23. Mexico gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 24. Mexico gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25. Europe gabapentin market, by country, 2018 - 2030 (USD Million)
  • Table 26. Europe gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 27. Europe gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 28. Europe gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 29. Europe gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. UK gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 31. UK gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 32. UK gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 33. UK Gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34. Germany gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 35. Germany gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 36. Germany gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 37. Germany gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38. France gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 39. France gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 40. France gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 41. France Gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42. Italy gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 43. Italy gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 44. Italy gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 45. Italy gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46. Spain gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 47. Spain gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 48. Spain gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 49. Spain gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50. Norway gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 51. Norway gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 52. Norway gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 53. Norway Gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54. Denmark gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 55. Denmark gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 56. Denmark gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 57. Denmark gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58. Sweden gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 59. Sweden gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 60. Sweden gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 61. Sweden gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62. Asia Pacific gabapentin market, by country, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 66. Asia Pacific gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67. Japan gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 68. Japan gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 69. Japan gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 70. Japan gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71. China gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 72. China gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 73. China gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 74. China gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75. India gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 76. India gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 77. India gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 78. India gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79. Australia gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 80. Australia gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 81. Australia gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 82. Australia gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83. South Korea gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 84. South Korea gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 85. South Korea gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 86. South Korea gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87. Thailand gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 88. Thailand gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 89. Thailand gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 90. Thailand gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91. Latin America gabapentin market, by country, 2018 - 2030 (USD Million)
  • Table 92. Latin America gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 93. Latin America gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 94. Latin America gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 95. Latin America gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 96. Brazil gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 97. Brazil gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 98. Brazil gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 99. Brazil gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 100. Argentina gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 101. Argentina gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 102. Argentina gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 103. Argentina gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104. Middle East & Africa Gabapentin market, by country, 2018 - 2030 (USD Million)
  • Table 105. Middle East & Africa gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 106. Middle East & Africa gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 107. Middle East & Africa gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 108. Middle East & Africa gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 109. South Africa gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 110. South Africa gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 111. South Africa gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 112. South Africa gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 113. Saudi Arabia gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 114. Saudi Arabia gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 115. Saudi Arabia gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 116. Saudi Arabia gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 117. UAE gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 118. UAE gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 119. UAE gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 120. UAE gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 121. Kuwait gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 122. Kuwait gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 123. Kuwait gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 124. Kuwait gabapentin market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Gabapentin market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Dosage form and type outlook (USD Million)
  • Fig. 10 Application and distribution channel outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Gabapentin market dynamics
  • Fig. 13 Gabapentin market: Porter's five forces analysis
  • Fig. 14 Gabapentin market: PESTLE analysis
  • Fig. 15 Gabapentin market: Dosage form segment dashboard
  • Fig. 16 Gabapentin market: Dosage form market share analysis, 2024 & 2030
  • Fig. 17 Tablet market, 2018 - 2030 (USD Million)
  • Fig. 18 Capsule market, 2018 - 2030 (USD Million)
  • Fig. 19 Oral solution market, 2018 - 2030 (USD Million)
  • Fig. 20 Gabapentin market: Type segment dashboard
  • Fig. 21 Gabapentin market: Type market share analysis, 2024 & 2030
  • Fig. 22 Generic market, 2018 - 2030 (USD Million)
  • Fig. 23 Branded market, 2018 - 2030 (USD Million)
  • Fig. 24 Gabapentin market: Application segment dashboard
  • Fig. 25 Gabapentin market: Application market share analysis, 2024 & 2030
  • Fig. 26 Epilepsy market, 2018 - 2030 (USD Million)
  • Fig. 27 Neuropathic pain market, 2018 - 2030 (USD Million)
  • Fig. 28 Restless legs syndrome market, 2018 - 2030 (USD Million)
  • Fig. 29 Others market, 2018 - 2030 (USD Million)
  • Fig. 30 Gabapentin market: Distribution channel segment dashboard
  • Fig. 31 Gabapentin market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 32 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 33 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 34 Online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 35 Gabapentin market revenue, by region
  • Fig. 36 Regional marketplace: Key takeaways
  • Fig. 37 Regional marketplace: Key takeaways
  • Fig. 38 North America gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. country dynamics
  • Fig. 40 U.S. gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 41 Canada country dynamics
  • Fig. 42 Canada gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 43 Mexico country dynamics
  • Fig. 44 Mexico gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 45 Europe gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 46 UK country dynamics
  • Fig. 47 UK gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 48 Germany country dynamics
  • Fig. 49 Germany gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 50 France country dynamics
  • Fig. 51 France gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 52 Italy country dynamics
  • Fig. 53 Italy gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 54 Spain country dynamics
  • Fig. 55 Spain gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 56 Norway country dynamics
  • Fig. 57 Norway gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 58 Sweden country dynamics
  • Fig. 59 Sweden gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 60 Denmark country dynamics
  • Fig. 61 Denmark gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 62 Asia Pacific gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 63 Japan country dynamics
  • Fig. 64 Japan gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 65 China country dynamics
  • Fig. 66 China gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 67 India country dynamics
  • Fig. 68 India gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 69 Australia country dynamics
  • Fig. 70 Australia gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 71 South Korea country dynamics
  • Fig. 72 South Korea gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 73 Thailand country dynamics
  • Fig. 74 Thailand gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 75 Latin America gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 76 Brazil country dynamics
  • Fig. 77 Brazil gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 78 Argentina country dynamics
  • Fig. 79 Argentina gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 80 MEA gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 81 South Africa country dynamics
  • Fig. 82 South Africa gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 83 Saudi Arabia country dynamics
  • Fig. 84 Saudi Arabia gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 85 UAE country dynamics
  • Fig. 86 UAE gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 87 Kuwait country dynamics
  • Fig. 88 Kuwait gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 89 Company categorization
  • Fig. 90 Company market position analysis
  • Fig. 91 Strategic framework